Clinical Efficacy of The Postbiotic Drug Biodonatum In Children with Pneumonia and Reduced Sensitivity to Antibiotic Therapy

Community-acquired pneumonia remains one of the leading causes of morbidity and mortality in the pediatric population worldwide, with antimicrobial resistance constituting a mounting threat to successful clinical management. The emergence and rapid dissemination of antibiotic-resistant bacterial strains have substantially reduced the therapeutic arsenal available to clinicians treating childhood pneumonia, necessitating the investigation of adjunctive treatment strategies capable of enhancing clinical recovery and restoring microbial equilibrium. This study aimed to evaluate the clinical efficacy, safety profile, and microbiome-modulating effects of the postbiotic preparation Biodonatum when administered as an adjunct to standard antibiotic therapy in children diagnosed with community-acquired pneumonia and demonstrating reduced sensitivity to first-line antibiotic agents. A prospective, randomized, controlled clinical trial was conducted at the Department of Pediatric Infectious Diseases, Tashkent State Medical University, enrolling 90 children aged 3 to 14 years with confirmed pneumonia and documented reduced antibiotic susceptibility. Participants were randomized into two equal groups: the intervention group (n = 45) received standard antibiotic therapy supplemented with Biodonatum, while the control group (n = 45) received standard antibiotic therapy alone. Clinical, laboratory, and microbiological parameters were assessed at baseline and on days 7 and 14 of treatment.

Ҳали таржима қилинмаган